Radium-223 re-treatment is safe for metastatic castration-resistant prostate cancer, per findings from the 2025 ASCO GU ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, ...

Radium-223 is an alpha-emitting radiopharmaceutical that accumulates in areas of high bone turnover and has demonstrated a survival benefit in metastatic prostate cancer, 1 but its benefits as a ...

From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...

Radium-223 re-treatment in mCRPC patients shows a low incidence of hematologic and non-hematologic adverse events, including skeletal-related events. The study reported a median overall survival of 16 ...

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

1 In radiopharmaceuticals, investigator-initiated research will be presented on XOFIGO ® (radium-223 dichloride) without ADT in patients with BCR and positron emission tomography (PET) findings in the ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

The Sensex recovered major losses to end flat as markets closed on February 18. The benchmark index recovered 436 points from ...

Austin Reaves scored a career-high 45 points and the streaking Los Angeles Lakers beat the Indiana Pacers 124-117 on Saturday ...

Vijayapura district to transform into an industrial hub with focus on renewable energy, tourism, and infrastructure ...